0750 GMT - Galderma posted strong first-quarter sales figures that increase confidence in its full-year guidance, RBC Capital Markets analysts Alistair Campbell and Charles Weston say in a research note. The Swiss skincare company reiterated its guidance for net sales growth at 10-12% at constant currency. However, it now includes the impact of recently announced U.S. tariffs on its fillers and biostimulators business in the U.S., which accounts for around 9% of total sales, the analysts say. Shares trade 6.2% higher at 85.60 Swiss francs. (nina.kienle@wsj.com)
(END) Dow Jones Newswires
April 24, 2025 03:51 ET (07:51 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.